Enhancing Accessibility: Ruxolitinib Cream and Improved Patient Access

EP: 1.Expert Insights: Unmet Needs in Topical Treatment for Atopic Dermatitis

EP: 2.Rapid Itch Relief With Topical Ruxolitinib: A Dermatological Perspective

EP: 3.Safety and Access Considerations: Topical Ruxolitinib Review

EP: 4.Clinical Perspectives: Addressing Unmet Needs in Topical Atopic Dermatitis Treatment

EP: 5.Understanding Efficacy and Real-World Application of Topical Non-Steroidal Treatments for AD

EP: 6.Insights on Topical Ruxolitinib: Rapid Itch Relief and Pediatric Considerations in Atopic Dermatitis

EP: 7.Ruxolitinib Cream vs. Corticosteroids in AD: Commentary on Location-Specific Safety and Continuous Use Potential

Now Viewing

EP: 8.Enhancing Accessibility: Ruxolitinib Cream and Improved Patient Access

EP: 9.Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 1

EP: 10.Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 2

EP: 11.Enhancing Atopic Dermatitis Treatment: Insights From Cutting-Edge Studies and Clinical Perspectives Part 3

EP: 12.Discovering Dermatology Times: May 2024 Enhancing Atopic Dermatitis Care Supplement

This is a video synopsis of a discussion involving James Del Rosso, DO, a dermatologist practicing in Las Vegas, Nevada, Brad Glick, DO, MPH, FAAD, a principal investigator at GSI Clinical Research in South Florida, and Lisa Swanson, MD, FAAD, a dermatologist and pediatric dermatologist based in Boise, Idaho.

The panelists delve into the challenges and advancements regarding access to topical ruxolitinib for treating atopic dermatitis (AD). Dr. Del Rosso emphasizes the initial difficulties in accessing the medication but highlights significant improvements, particularly in Idaho, Florida, and Nevada. He underscores the efficacy of ruxolitinib in addressing mild to moderate AD and encourages patients to revisit the option.

Dr. Swanson offers assistance to individuals facing access issues, highlighting her willingness to aid in navigating the process. Dr. Glick mentions the availability of preform letters from the American Academy of Dermatology's Practice Management Center.

The panelists express optimism about the evolving treatment landscape, particularly with the advent of new systemic therapeutics. They commend the effectiveness of ruxolitinib and the increased availability of samples, emphasizing the importance of persistence in overcoming initial obstacles. The discussion concludes with appreciation for the opportunity to collaborate and share insights on managing AD effectively.

Video synopsis is AI-generated and reviewed by Dermatology Times® editorial staff.